Unimark Remedies Profile
Key Indicators
- Authorised Capital ₹ 57.01 Cr
as on 15-12-2024
- Paid Up Capital ₹ 10.00 Cr
as on 15-12-2024
- Company Age 31 Year, 19 Days
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 2,009.70 Cr
as on 15-12-2024
- Satisfied Charges ₹ 153.67 Cr
as on 15-12-2024
- Revenue -30.01%
(FY 2019)
- Profit 38.94%
(FY 2019)
- Ebitda 60.24%
(FY 2019)
- Net Worth -30.94%
(FY 2019)
- Total Assets -8.66%
(FY 2019)
About Unimark Remedies
The Corporate was formerly known as Unimark Remedies Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 57.01 Cr and a paid-up capital of Rs 10.00 Cr.
The company currently has active open charges totaling ₹2,009.70 Cr. The company has closed loans amounting to ₹153.67 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kamlesh Khokhani, Jitesh Rameshchandra, and Ketan Parikh serve as directors at the Company.
- CIN/LLPIN
U23200MH1993PLC075373
- Company No.
075373
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
01 Dec 1993
- Date of AGM
29 Dec 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Unimark Remedies Limited offer?
Unimark Remedies Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API, Anti Infective Drugs & Medicines, Antibacterial Drugs.
Who are the key members and board of directors at Unimark Remedies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamlesh Khokhani  | Director | 26-May-2023 | Current |
| Jitesh Rameshchandra | Director | 26-May-2023 | Current |
| Ketan Parikh | Additional Director | 27-May-2023 | Current |
Financial Performance and Corporate Structure Insights of Unimark Remedies.
Unimark Remedies Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 30.01% decrease. The company also saw a substantial improvement in profitability, with a 38.94% increase in profit. The company's net worth observed a substantial decline by a decrease of 30.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unimark Remedies?
In 2018, Unimark Remedies had a promoter holding of 18.08% and a public holding of 81.92%. The company had 2 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shamrock Pharmachemi Private LimitedActive 43 years 6 monthsKamlesh Khokhani and Ketan Parikh are mutual person
- Raajshi Invecorp LlpActive 10 years 9 months
Kamlesh Khokhani and Jitesh Rameshchandra are mutual person
- Shamrock Steriotech LlpActive 10 years 9 months
Kamlesh Khokhani and Jitesh Rameshchandra are mutual person
- Shiraj Invecorp LlpActive 10 years 8 months
Kamlesh Khokhani and Jitesh Rameshchandra are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Jul 2024 | ₹50.00 Cr | Open |
Idbi Trusteeship Services Limited Creation Date: 03 Jun 2014 | ₹913.75 Cr | Open |
Bank Of India Creation Date: 06 Mar 2013 | ₹12.00 Cr | Open |
How Many Employees Work at Unimark Remedies?
Unimark Remedies has a workforce of 4 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unimark Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unimark Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
